What Are the Common Reasons for Request for Information (RFI) in Overseas Registration Dossiers for Laboratory Equipment?

What Are the Common Reasons for Request for Information (RFI) in Overseas Registration Dossiers for Laboratory Equipment?

When a laboratory equipment registration is submitted overseas, a Request for Information (RFI) or deficiency notice is generally not a reflection of product failure. Instead, it indicates that the submitted documentation does not align with the target country's regulatory framework, often because the manufacturer has not structured the evidence according to local requirements. The most common reasons include incorrect product classification, a mismatch between intended use and clinical evidence, incomplete risk management documentation, performance verification not covering target market expectations, labels and instructions not meeting local language and content rules, missing local authorized representative or manufacturer authorization, and failure to submit a post-market surveillance plan.

Key Summary

Laboratory equipment receiving a deficiency notice during overseas registration is usually due to documentation not being prepared in the context of the target country's regulatory framework. First, determine whether the equipment falls under the medical device regulatory scope of the target country. For instance, PCR analyzers and biochemical analyzers used for clinical sample testing are typically regulated as IVDs or medical devices, while a standard research centrifuge may not be considered a medical device. Then, confirm the risk classification and the applicable registration pathway, as different countries impose different technical file requirements.

Common RFI reasons include: incorrect product classification, intended use description inconsistent with clinical evidence, incomplete risk management report, performance validation protocols not covering target market requirements, labels and instructions not in the required local language, absence of a local authorized representative or manufacturer authorization, and no post-market surveillance plan. Manufacturers should perform classification determination early, assess how much existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation can be reused, and prepare a localization package for GHWP member countries, Southeast Asia, the Middle East, Latin America, and other markets.

This article lists the seven categories of issues most frequently cited in deficiency letters and provides pre-submission audit methods and evidence-chain construction approaches to help companies shorten the registration cycle.

Applicable Scenarios and Core Issues

Laboratory equipment exporters often encounter the first major hurdle in the form of an RFI. It does not mean the product is defective or that the company lacks technical ability; rather, the submission fails to form a complete evidence chain within the applicable regulatory framework. Laboratory equipment covers a wide range, including PCR instruments, centrifuges, biochemical analyzers, microplate readers, washers, incubating shakers, biosafety cabinets, and more. Some of these devices are classified as medical devices or IVD instruments in certain countries, while others may be ordinary laboratory instruments. If the classification is wrong, the entire subsequent registration path will be misaligned.

A common mistake is to apply China's NMPA registration requirements directly overseas, or to assume that an existing CE or FDA clearance can be submitted unchanged to other countries. In reality, each country has its own laws and regulatory traditions, and requirements for technical documentation, quality systems, clinical evaluation, label language, and agent responsibilities differ significantly. An RFI essentially means the regulator finds the submitted information insufficient to demonstrate safety and effectiveness, or that there are deviations from local expectations.

This article is intended for manufacturers, CROs, and overseas business leaders who are preparing for registration or have already received an RFI. The core question is: what are the common reasons for RFIs in overseas registration of laboratory equipment, and how can companies systematically avoid these reasons? We will not focus on filling out specific country application forms; instead, we will clarify the underlying logic and preparation strategy.

Registration Determination Logic

The first step to avoiding an RFI is not to start translating instructions immediately, but to conduct a formal regulatory classification assessment in the target country. The same laboratory device may be regulated as a Class II medical device in China, as a Class B IVD in Malaysia, or under a different risk level in the UAE. Classification requires reviewing the official classification rules, exemption lists, and approval pathways of similar products in the target country.

The second step is to determine the risk class and the corresponding registration pathway. Risk class directly determines the technical file checklist, the review duration, whether clinical investigation is needed, and whether local testing is required. Many companies mistakenly assume that all laboratory equipment is low risk and overlook that instruments with diagnostic purposes are often classified as moderate or high risk, leading to inadequate preparation.

The third step is to evaluate how reusable existing documentation is. If a company already possesses technical files that meet NMPA, CE, FDA, or MDSAP requirements, these can be mapped to the target country's CTD format quickly. However, note that an ISO 13485 certificate is not automatically accepted by all countries. Some countries require submission of quality system evidence recognized by the local regulator or additional audit reports.

The fourth step is to confirm the specific deliverables to submit. These must include the full technical file, performance validation reports, risk management records, clinical evaluation or clinical evidence, labeled instruction language versions, local agent and authorized representative information, and a post-market surveillance plan. The key at this level is to understand whether the target country follows a “technical document review” model or an “recognition of existing evidence” model. While GHWP member states have shown certain harmonization trends, localization remains an unavoidable step.

Technical Documentation and Evidence

The essence of laboratory equipment registration documentation is to prove that the product is safe and effective for its intended use and that target-country users can operate it correctly. Thus, deficiency responses typically revolve around product definition, performance data, and risk control. The product definition section must clearly state the device name, model, intended use, environment of use, target user population, and whether it is intended to assist in diagnosis. Many companies write this part too vaguely, mixing research and clinical purposes, which makes it impossible for regulators to judge the intended scope.

Performance verification documentation is a major area of RFIs. Laboratory equipment often requires precise data on precision, accuracy, linear range, detection limit, repeatability, environmental stability, and software validation. Some companies directly use reports from third-party labs generated for CE registration, but the target country may not recognize the laboratory's qualification or may require re-testing according to local standards. For example, in Saudi Arabia or Brazil, some tests must be conducted locally.

Risk management reports must include complete analysis and control measures according to ISO 14971 or an acceptable national standard. Laboratory equipment often involves risks such as chemical exposure, electrical safety, biological hazards, data leaks, and operator errors. Providing only a risk analysis table without clear risk control measures, residual risk evaluation, and benefit-risk conclusions is almost certain to trigger an RFI.

Clinical evaluation or clinical evidence does not necessarily require conducting new clinical trials. However, for the intended use and risk class, a systematic review, literature, or clinical study data must be submitted. For laboratory equipment that claims diagnostic or monitoring functions, it is almost inevitable to receive an RFI if sample comparison data against a reference method is missing.

Labels and instructions are another major area. Different countries require labels in at least the official language, and some also require specific warning statements, units, and symbols. Many companies translate only the instructions and disregard the device label, packaging label, or electronic label compliance. In addition, the intended use description in the instructions must align with the registered content; there must be no exaggeration of performance or addition of unapproved use scenarios.

Local agent and authorized representative documents are critical. The United States, the European Union, Gulf countries, and most Southeast Asian countries require a designated local registrant. Without an effective agency agreement, authorization certificate, or business license of the local agent, review cannot proceed. The post-market surveillance plan must include complaint handling, adverse event reporting, vigilance system, and update procedures. This section is often overlooked in initial submissions.

Common Mistakes

• Not performing classification assessment for the target country, leading to wrong format and template.
• Overly broad intended use description that does not match the product's actual function, such as presenting a research device as a clinical diagnostic tool.
• Incomplete risk management report, listing risk codes without mapping to safety objectives or verifying control effectiveness.
• Performance validation protocols that do not align with local reference standards, e.g., sample type, statistical methods, or acceptance criteria not accepted by target-country reviewers.
• Labels and instructions in English only, lacking local language versions, or warnings not placed correctly.
• Missing or outdated local agent / authorized representative information, expired agency agreement, or incomplete authorization scope.
• Reusing technical reports from other countries without indicating sources and applicability, such as directly binding a CE report in a GHWP country submission without a gap analysis.
• Post-market surveillance plan missing or empty, without concrete procedures or assigned responsibility.

Company Preparation Checklist

• Complete a written classification and registration pathway assessment before project kickoff, and prepare a classification memorandum signed by regulatory personnel.
• Establish a “Target Country Technical File Requirements Mapping Table” and identify gaps in existing evidence, including reusable NMPA, CE, FDA, ISO 13485, and MDSAP documentation.
• Designate a local agent and sign a formal authorization agreement, ensuring the agency has a robust regulatory service quality system and renewal support capabilities.
• Organize a joint review by R&D, quality, and regulatory teams of the intended use, labels, and instructions to ensure accuracy and alignment with the submission.
• Commission tests to be conducted at a laboratory recognized by the target country, and retain raw data, certificates, and qualification evidence.
• Develop a risk management file template that ensures every risk item includes identification, analysis, evaluation, control, residual risk, and overall judgment.
• Write a post-market surveillance plan that defines complaint feedback pathways, adverse event reporting timelines, periodic data collection, and update mechanisms.
• Create a modular technical documentation package for multi-country registration, separating common data from country-specific requirements to facilitate rapid conversion.

AIMEILI Regulatory Interpretation and Business Impact

The root cause of RFIs for laboratory equipment overseas registration is not that the documentation is insufficient in quantity, but that it is not organized according to the target country's regulatory logic. The most common misjudgment is treating the product as an ordinary analytical instrument and overlooking that the target country may regulate it as a medical device or IVD. We recommend performing classification determination at the earliest possible stage, ideally during product design freeze, and involving experienced regulatory consultants to avoid late-stage testing gaps.

The most worthwhile investment in the early phase is a documentation gap analysis. Do not start translating all documents at once. Instead, spend a week building a checklist of target country submission requirements and compare them line by line with existing technical files. ISO 13485 and CE documentation are often reusable, but an applicability assessment must be conducted before reuse—particularly for performance validation sample sizes, test standard editions, and regulatory references used in risk analysis. The items that are usually not reusable are localization content, including label language, agent documents, country-specific test reports, and local ethics or clinical requirements.

Local agents and certificate ownership are often hidden causes of deficiency letters. Some companies authorize an agent to handle registration but the certificate is held under the agent's name. If the agent is changed or a dispute arises, the entire registration status may be affected. We advise manufacturers to explicitly define certificate ownership, amendment rights, and renewal responsibilities in the agreement, and to require the agent to provide regular submission updates and regulatory communication records.

For multi-country registrations, the risk of duplicated rework and RFIs largely stems from manually copying technical content. We recommend managing documents in two layers: a “core technical file package” and a “country-specific file package.” The core package includes product description, performance validation, risk management, and quality system certificates. The country-specific package includes agency agreements, translated labels, local test reports, and registration application forms. This structure allows new product certifications to be assembled without starting from scratch, reducing omissions and contradictions.

Common Follow-up Questions

Are local test reports mandatory for lab equipment overseas registration?

Not always, depending on the target country. For example, Brazil, Saudi Arabia, and Russia require local testing for certain high-risk laboratory equipment, while many Southeast Asian countries accept non-local laboratory reports that comply with ISO standards. We recommend confirming the latest requirements with the target country or a reliable regulatory partner to avoid asset rejection due to unrecognized laboratory qualifications.

Can I directly submit CE files for registration in another country if I already have CE marking?

No, you cannot submit CE files directly. CE documentation is an important foundation but must be reorganized in the target country's format with a gap analysis. For example, GHWP member countries generally require a CTD-like file list, and some countries require an explanation of the mapping between CE documents and local regulations. Missing formalities or language translation can cause an RFI. The correct approach is to retain the original CE reports and recompile them according to the target country's template.

How much time is available to prepare responses after receiving an RFI?

Timelines vary by country, typically ranging from 30 to 90 working days, with some countries allowing a single extension. When an RFI is received, first confirm the deadline, the response submission window, and the consequences of not submitting on time. If certain deficiency items require new testing or a new agent agreement, start preparation in parallel and do not wait until all materials are ready before responding, to avoid missing the deadline.

Continue Reading

For more practical guidance on medical device international registration, visit AIMEILI's FAQ Center or contact AIMEILI for regulatory consultation.